Tag: antibody drug conjugate

FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE

businessnewstoday- March 24, 2024

AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More

Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial

businessnewstoday- July 30, 2023

The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival ... Read More

LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305

businessnewstoday- May 14, 2023

LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug conjugate (ADC) called LM-305 with AstraZeneca. LM-305 ... Read More

Enhertu EU approval : Daiichi Sankyo, AstraZeneca get approval for HER2 low metastatic breast cancer

Raghuram Kadari- January 29, 2023

Daiichi Sankyo and AstraZeneca have received the approval of the European Union (EU) for their jointly developed Enhertu (trastuzumab deruxtecan) for the treatment of a ... Read More

AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer

pallavi123- August 7, 2022

Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment ... Read More

DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response

pallavi123- September 18, 2021

AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric ... Read More